Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
FULC Fulcrum Therapeutics	$6.88 +5.5%	$7.11	$2.32 ▼ $9.90	$372.15M	2.47	984,909 shs	362,286 shs
NBTX Nanobiotix	$10.09 +3.6%	$6.11	$2.76 ▼ $10.59	$483.95M	0.45	13,300 shs	41,490 shs
OLMA Olema Pharmaceuticals	$5.76 +4.0%	$4.79	$2.86 ▼ $13.93	$395.33M	1.92	535,497 shs	432,641 shs
ZOM Zomedica		$0.12	$0.09 ▼ $0.16	$95.35M	1.03	4.72 million shs	790,936 shs

7 Stocks That Could Be Bigger Than Tesla, Nvidia, and Google

Looking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
FULC Fulcrum Therapeutics	+5.52%	+0.88%	-13.02%	+6.83%	-27.88%
NBTX Nanobiotix	+3.59%	+27.56%	+73.22%	+165.60%	+112.42%
OLMA Olema Pharmaceuticals	+3.97%	+4.54%	+23.61%	+14.29%	-53.55%
ZOM Zomedica	0.00%	0.00%	0.00%	0.00%	-30.51%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
FULC Fulcrum Therapeutics	0.9437 of 5 stars	2.3	1.0	0.0	0.0	2.2	1.7	0.0
NBTX Nanobiotix	0.8793 of 5 stars	1.3	3.0	0.0	0.0	3.5	0.0	0.6
OLMA Olema Pharmaceuticals	1.6565 of 5 stars	3.3	0.0	0.0	0.0	2.5	2.5	0.0
ZOM Zomedica	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
FULC Fulcrum Therapeutics	2.63	Moderate Buy	$7.57	10.05% Upside
NBTX Nanobiotix	2.50	Moderate Buy	$8.00	-20.71% Downside
OLMA Olema Pharmaceuticals	2.67	Moderate Buy	$24.00	316.67% Upside
ZOM Zomedica	4.00	Strong Buy	N/A	N/A

Current Analyst Ratings Breakdown

Latest ZOM, NBTX, OLMA, and FULC Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/14/2025	OLMA Olema Pharmaceuticals	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$28.00 ➝ $29.00
8/12/2025	OLMA Olema Pharmaceuticals	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$20.00 ➝ $21.00
8/11/2025	OLMA Olema Pharmaceuticals	Zacks Research Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong Sell
7/30/2025	FULC Fulcrum Therapeutics	Royal Bank Of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Sector Perform ➝ Sector Perform	$4.00 ➝ $5.00
7/29/2025	FULC Fulcrum Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Neutral ➝ Buy	$4.00 ➝ $12.00
5/29/2025	FULC Fulcrum Therapeutics	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Overweight	$6.00 ➝ $9.00
5/23/2025	FULC Fulcrum Therapeutics	Leerink Partnrs Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Hold ➝ Strong-Buy
5/23/2025	FULC Fulcrum Therapeutics	Leerink Partners Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Market Perform ➝ Outperform	$4.00 ➝ $12.00

(Data available from 8/23/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
FULC Fulcrum Therapeutics	$80M	4.65	N/A	N/A	$3.96 per share	1.74
NBTX Nanobiotix	$39.18M	12.35	N/A	N/A	($1.51) per share	-6.68
OLMA Olema Pharmaceuticals	N/A	N/A	N/A	N/A	$5.03 per share	N/A
ZOM Zomedica	$25.19M	0.00	N/A	N/A	$0.24 per share	0.00

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
FULC Fulcrum Therapeutics	-$9.73M	-$1.22	N/A	N/A	N/A	N/A	-31.05%	-28.96%	N/A
NBTX Nanobiotix	-$73.73M	N/A	0.00	N/A	N/A	N/A	N/A	N/A	9/17/2025 (Estimated)
OLMA Olema Pharmaceuticals	-$129.47M	-$1.98	N/A	N/A	N/A	N/A	-42.58%	-38.65%	11/11/2025 (Estimated)
ZOM Zomedica	-$34.53M	-$0.06	N/A	N/A	N/A	-232.88%	-12.47%	-11.84%	N/A

Latest ZOM, NBTX, OLMA, and FULC Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue	Details
8/11/2025	Q2 2025	OLMA Olema Pharmaceuticals	-$0.43	-$0.51	-$0.08	-$0.51	N/A	N/A
7/29/2025	Q2 2025	FULC Fulcrum Therapeutics	-$0.29	-$0.28	+$0.01	-$0.28	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
FULC Fulcrum Therapeutics	N/A	N/A	N/A	N/A	N/A
NBTX Nanobiotix	N/A	N/A	N/A	N/A	N/A
OLMA Olema Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
ZOM Zomedica	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
FULC Fulcrum Therapeutics	N/A	24.42	24.42
NBTX Nanobiotix	N/A	1.04	1.04
OLMA Olema Pharmaceuticals	0.01	11.09	11.09
ZOM Zomedica	N/A	10.82	10.15

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
FULC Fulcrum Therapeutics	89.83%
NBTX Nanobiotix	38.81%
OLMA Olema Pharmaceuticals	91.78%
ZOM Zomedica	8.95%

Insider Ownership

Company	Insider Ownership
FULC Fulcrum Therapeutics	7.00%
NBTX Nanobiotix	3.45%
OLMA Olema Pharmaceuticals	16.36%
ZOM Zomedica	4.19%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
FULC Fulcrum Therapeutics	100	54.09 million	50.31 million	Optionable
NBTX Nanobiotix	100	47.94 million	46.29 million	Not Optionable
OLMA Olema Pharmaceuticals	70	68.63 million	57.41 million	Optionable
ZOM Zomedica	50	979.95 million	938.89 million	Not Optionable

ZOM, NBTX, OLMA, and FULC Headlines

Recent News About These Companies

Zomedica Corp.: Zomedica and VerticalVet Announce Strategic Partnership to Deliver Advanced Veterinary Technologies to Independent Practices

August 19, 2025 | finanznachrichten.de

Zomedica Corp.: Zomedica's Fourth Friday at Four Webinar Returns: Spotlight on the VETIGEL Hemostatic Product - The Future of Rapid Bleeding Control in Veterinary Medicine

August 12, 2025 | finanznachrichten.de

Zomedica Achieves Record Revenue Growth in Q2 2025

August 6, 2025 | msn.com

Non-Pharmacologic Solutions for Pet Dental Health From Prevention to Recovery

July 11, 2025 | dvm360.comD

Zomedica Corp.: Zomedica Announces Strategic PulseVet Shock Wave Partnership with World Equestrian Center - Ocala

July 10, 2025 | finanznachrichten.de

Zomedica Announces Issuance of Additional Patent for its TRUVIEW (R) Microscope - Morningstar

June 25, 2025 | morningstar.comM

Zomedica Corp.: Zomedica Unveils Exclusive Fourth Friday at Four Webinar Series to Explore Cutting-Edge Veterinary Innovations

May 20, 2025 | finanznachrichten.de

Treat pet pain, inflammation, and anxiety with this high-tech at home therapy

April 24, 2025 | click2houston.comC

Helping Pets Live Pain-Free: High-Tech Treatments for Our Four-Legged Family Members

April 11, 2025 | pix11.comP

Is Zomedica Corp. (ZOMDF) the Cheapest Stock Insiders Are Buying In March?

March 28, 2025 | insidermonkey.com

15 Cheapest Stocks Insiders Are Buying In March

March 27, 2025 | insidermonkey.com

Earnings call transcript: Zomedica Q4 2024 shows revenue growth

March 15, 2025 | investing.com

Q4 2024 Zomedica Corp Earnings Call

March 15, 2025 | finance.yahoo.com

Zomedica Corp. (ZOMDF) Q4 2024 Earnings Call Transcript

March 13, 2025 | seekingalpha.com

Zomedica (ZOMDF) Gets a Buy from Noble Financial

March 11, 2025 | markets.businessinsider.com

Zomedica Corp.

March 8, 2025 | wsj.com

Zomedica Corp. Announces Transition to OTCQB Venture Market

March 4, 2025 | accessnewswire.comA

NYSE American to Commence Delisting Proceedings Against Zomedica Corp. (ZOM)

March 4, 2025 | businesswire.com

Zomedica to Report Fourth Quarter and Full Year 2024 Financial Results with a Business Update on March 13th at 4:30 p.m. ET

February 26, 2025 | accessnewswire.comA

Zomedica Corp.: Zomedica Improves Efficiency and Cuts Costs by Moving to New Headquarters

February 12, 2025 | finanznachrichten.de

New MarketBeat Followers Over Time

Media Sentiment Over Time

ZOM, NBTX, OLMA, and FULC Company Descriptions

Fulcrum Therapeutics NASDAQ:FULC

$6.88 +0.36 (+5.52%)

Closing price 08/22/2025 04:00 PM Eastern

Extended Trading

$6.88 +0.00 (+0.01%)

As of 08/22/2025 05:10 PM Eastern

Fulcrum Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing products for improving the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Its product candidates are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystrophy is under phase III clinical trial; and pociredir, a fetal hemoglobin inducer for the treatment of sickle cell disease and beta-thalassemia is under phase I clinical trial. The company is also discovering drug targets for the treatments of rare neuromuscular, muscular, central nervous system, and hematologic disorders, as well as cardiomyopathies and pulmonary diseases. Fulcrum Therapeutics, Inc. has collaboration and license agreement with Acceleron Pharma Inc. to identify biological targets to modulate specific pathways associated with a targeted indication within the pulmonary disease space; and MyoKardia, Inc. to discover and develop therapies for the treatment of genetic cardiomyopathies. Fulcrum Therapeutics, Inc. was Incorporated in 2015 and is headquartered in Cambridge, Massachusetts.

Nanobiotix NASDAQ:NBTX

$10.09 +0.35 (+3.59%)

Closing price 08/22/2025 03:51 PM Eastern

Extended Trading

$10.35 +0.26 (+2.58%)

As of 08/22/2025 05:27 PM Eastern

Nanobiotix S.A., a clinical-stage biotechnology, focuses on developing product candidates for the treatment of cancer and other unmet medical needs. Its lead product candidate is NBTXR3, a sterile aqueous suspension of crystalline hafnium oxide nanoparticles used for the treatment of soft tissue sarcoma, head and neck cancers, liver cancers, prostate cancer, pancreatic cancer, esophageal cancer, rectal cancer, and non-small cell lung cancer. The company has a partnership with Lian Oncology Limited to develop and commercialize NBTXR3 in Greater China, South Korea, Singapore, and Thailand. Nanobiotix S.A. was incorporated in 2003 and is headquartered in Paris, France.

Olema Pharmaceuticals NASDAQ:OLMA

$5.76 +0.22 (+3.97%)

Closing price 08/22/2025 04:00 PM Eastern

Extended Trading

$5.76 0.00 (-0.09%)

As of 08/22/2025 04:10 PM Eastern

Olema Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women's cancers. Its lead product candidate is OP-1250, an estrogen receptor (ER) antagonist and a selective ER degrader, which is in Phase 3 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer; and OP-1250 combine with CDK4/6 inhibitors palbociclib, ribociclib, and alpelisib in Phase 1/2 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive human epidermal growth factor receptor 2-negative breast cancer, as well as develops OPERA-01 for the of ER+/HER2- advanced or metastatic breast cancer. The company was formerly known as CombiThera, Inc. and changed its name to Olema Pharmaceuticals, Inc. in March 2009. Olema Pharmaceuticals, Inc. was incorporated in 2006 and is headquartered in San Francisco, California.

Zomedica NYSEAMERICAN:ZOM

Zomedica Corp., a veterinary health company, focuses on the unmet needs of clinical veterinarians by developing products for companion animals. The company offers diagnostic products comprising TRUFORMA Bulk Acoustic Wave point of care diagnostic platform; TRUVIEW, a digital cystoscopy platform that offers automated slide preparation within the instrument; and VetGuardian, a zero-touch vital signs remote monitoring system. It also provides therapeutic products, including PulseVet electrohydraulic shockwave therapy platform; and Assisi Loop line of products, including the Assisi Loop, Assisi Loop Lounge, and DentaLoop devices that treat pain and inflammation through delivery of targeted pulsed electromagnetic field focused energy. The company has collaboration agreements with Celsee, Inc. for the development and commercialization of liquid biopsy assays and related consumables for the detection of cancer in companion animals; and Seraph Biosciences, Inc. for the development of a novel pathogen detection system. The company was formerly known as Zomedica Pharmaceuticals Corp. and changed its name to Zomedica Corp. in October 2020. Zomedica Corp. is headquartered in Ann Arbor, Michigan.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time